Karuna completes data package for schizophrenia drug ahead of filing

21 March 2023

US psychiatric and neurological conditions specialist Karuna Therapeutics (Nasdaq: KRTX) has announced top-line results from its Phase III EMERGENT-3 trial of its lead investigational therapy, KarXT (xanomeline-trospium) in schizophrenia.

As with the two previous registrational studies that went before it, this trial met its primary endpoint, with KarXT demonstrating a statistically-significant and clinically-meaningful 8.4-point reduction in positive and negative syndrome scale (PANSS) total score compared to placebo at week five.

"We are one step closer to a potential treatment option that could provide the first new mechanism of action to treat schizophrenia in several decades"Consistent with prior trials, the investigational M1/M4-preferring muscarinic agonist demonstrated an early and sustained statistically significant reduction of symptoms from week two through the end of the trial as assessed by PANSS total score.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK